Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.
Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.